Literature DB >> 32943162

Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention.

Maneesh Sud1, Lu Han2, Maria Koh2, Husam Abdel-Qadir3, Peter C Austin4, Michael E Farkouh5, Lucas C Godoy6, Patrick R Lawler5, Jacob A Udell3, Harindra C Wijeysundera1, Dennis T Ko7.   

Abstract

BACKGROUND: After percutaneous coronary interventions (PCIs), patients remain at high risk of developing late cardiovascular events. Although controlling low-density lipoprotein cholesterol (LDL-C) may improve outcomes after PCI, practice guidelines do not have specific recommendations on LDL-C management for this subgroup.
OBJECTIVES: The purpose of this study was to evaluate LDL-C testing and levels after PCIs, and to assess the association between LDL-C and longer-term cardiovascular events after PCIs.
METHODS: All patients who received their first PCI from October 1, 2011, to September 30, 2014, in Ontario, Canada, were considered for inclusion. Patients who had LDL-C measurement within 6 months after PCI were categorized as: <70 mg/dl, 70 to <100 mg/dl, and ≥100 mg/dl. The primary composite outcome was cardiovascular death, myocardial infarction, coronary revascularization, and stroke through December 31, 2016.
RESULTS: Among 47,884 included patients, 52% had LDL-C measured within 6 months of PCI and 57% had LDL-C <70 mg/dl. After a median 3.2 years, the rates of cardiovascular events were 55.2/1,000 person-years for the LDL-C <70 mg/dl group, 60.3/1,000 person-years for 70 to <100 mg/dl, and 94.0/1,000 person-years for ≥100 mg/dl. The adjusted subdistribution hazard ratios for cardiovascular events were 1.17 (95% confidence interval: 1.09 to 1.26) for LDL-C of 70 to <100 mg/dl, and 1.78 (95% confidence interval: 1.64 to 1.94) for LDL-C ≥100 mg/dl when compared with LDL-C <70 mg/dl.
CONCLUSIONS: One in 2 patients had LDL-C measured within 6 months after PCI, and only 57% had LDL-C <70 mg/dl. Higher levels of LDL-C were associated with an increased incidence of late cardiovascular events. Improved cholesterol management after PCI should be considered to improve the outcomes of these patients.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute coronary syndromes; low-density lipoprotein cholesterol; percutaneous coronary intervention; secondary prevention; stable coronary artery disease

Year:  2020        PMID: 32943162     DOI: 10.1016/j.jacc.2020.07.033

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention.

Authors:  Shuting Kong; Changxi Chen; Gaoshu Zheng; Hui Yao; Junfeng Li; Hong Ye; Xiaobo Wang; Xiang Qu; Xiaodong Zhou; Yucheng Lu; Hao Zhou
Journal:  BMC Cardiovasc Disord       Date:  2021-05-22       Impact factor: 2.298

2.  Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.

Authors:  Erin S Mackinnon; Ron Goeree; Shaun G Goodman; Raina M Rogoza; Millicent Packalen; Louisa Pericleous; Ponda Motsepe-Ditshego; Paul Oh
Journal:  CJC Open       Date:  2021-10-20

3.  The 5th Annual Heart in Diabetes Conference (part 2).

Authors:  Zachary Bloomgarden
Journal:  J Diabetes       Date:  2022-01-24       Impact factor: 4.530

4.  Low-Density Lipoprotein Cholesterol and Mortality Risk in Elderly Patients Undergoing Valve Replacement Surgery: A Propensity Score Matching Analysis.

Authors:  Han-Biao Li; Bing-Qi Fu; Tong Tan; Xiao-Hua Li; Shou-Hong Wang; Xue-Biao Wei; Zhong-Hua Wang
Journal:  Front Nutr       Date:  2022-04-28

5.  Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study.

Authors:  Milan Gupta; G B John Mancini; Rajvi J Wani; Vineeta Ahooja; Jean Bergeron; Priya Manjoo; A Shekhar Pandey; Maureen Reiner; Johnny Beltran; Thiago Oliveira; Erin S Mackinnon
Journal:  CJC Open       Date:  2022-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.